Group 1 - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. due to allegations of materially misleading business information [1] - Investors who purchased Telix securities may be entitled to compensation through a contingency fee arrangement, with a class action being prepared to recover investor losses [2] - Telix disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission regarding its disclosures related to prostate cancer therapeutic candidates, leading to a 10.44% drop in its ADR price [4] Group 2 - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [5]
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX